CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.70009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Riya Thapa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India. Hauptthemen laut MEDLINE: Neoplasms, Ubiquitin-Protein Ligases, Proteolysis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 280 Literaturangaben.
Abstract (Originalsprache)
Cereblon (CRBN), a member of the E3 ubiquitin ligase complex, has gained significant attention as a therapeutic target in cancer. CRBN regulates the degradation of various proteins in cancer progression, including transcription factors and signaling molecules. PROTACs (proteolysis‐targeting chimeras) are a novel approach that uses the cell's degradation system to remove disease‐causing proteins selectively. CRBN‐dependent PROTACs work by tagging harmful proteins for destruction through the ubiquitin–proteasome system. This strategy offers several advantages over traditional protein inhibition methods, including the potential to overcome drug resistance. Recent progress in developing CRBN‐based PROTACs has shown promising preclinical results in both hematologic malignancies and solid tumors. Additionally, CRBN‐based PROTACs have enhanced our understanding of CRBN's role in cancer, potentially serving as biomarkers for patient stratification and predicting therapeutic responses. In this review, we delineate the mechanisms of action for CRBN‐dependent PROTACs (CRBN‐PROTACs), summarize recent advances in preclinical and clinical applications, and provide our perspective on future development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
- Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, UAE.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
- Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, India.
- NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India.
ORCID-Profile: Haider Ali
Zitieren
APA
Thapa, R., Bhat, A. A., Gupta, G., Renuka Jyothi, S., Kaur, I., Kumar, S., Sharma, N., Prasad, G. V. S., Pramanik, A., & Ali, H. (2024). CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70009
Vancouver
Thapa R, Bhat AA, Gupta G, Renuka Jyothi S, Kaur I, Kumar S, et al. CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70009
BibTeX
@article{Thapa2024,
author = {Thapa, Riya and Bhat, Asif Ahmad and Gupta, Gaurav and Renuka Jyothi, S and Kaur, Irwanjot and Kumar, Sachin and Sharma, Naveen and Prasad, G V Siva and Pramanik, Atreyi and Ali, Haider},
title = {CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.70009}
}
EUVIMED